TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
NCT04599777
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG:
TACE combined with sorafenib and tislelizumab
Sponsor
Second Affiliated Hospital of Guangzhou Medical University